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SUMMARY 
Background: The aim of our study is to systematically review the existing evidence 
on the role of Corticosteroids in patients undergoing Functional Endoscopic Sinus 
Surgery (FESS). 
Methodology: Systematic search of MEDLINE (1950- 2014), EMBASE (1980-2014), 
metaRegister, Cochrane Library and ISI conference proceedings was carried out.  
Result - Eighteen randomised controlled trials with 1309 patients were included. Use 
of local or systemic corticosteroids with FESS was reported in four categories; 
operative, anaesthesia related, post-operative outcomes and risk of recurrence. Meta-
analysis for operative outcomes demonstrated that, mean operative time (MD -10.70 
minutes; 95% CI -15.86, -5.55; P <0.0001) and mean estimated blood loss (MD -
28.32 mls; 95% CI -40.93, -15.72; P <0.0001) was significantly lower; and surgical 
field quality (MD -0.81; 95% CI -1.32, -0.30; P = 0.002) was significantly better in 
corticosteroid group. Meta-analysis showed that post-operative endoscopic scores 
(SMD   -0.39; 95% CI -0.60, -0.17; P = 0.0004) were significantly better in 
corticosteroid group compared to no corticosteroid group. There was no increase in 
risk of sinusitis (RR 0.64; 95% CI 0.32, 1.30; P = 0.22) between use of corticosteroids 
and no corticosteroids; There was no significant difference in recurrence risk of 
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Chronic Rhinosinusitis (CRS)  in mixed population studies (RR 0.77; 95% CI 0.35, 
1.70; P = 0.52) between the two groups but analysis of studies reporting on Chronic 
Rhinosinusitis with Nasal Polyps (CRSwNP) (RR 0.64;95% CI 0.45,0.91;P=0.01) 
showed significant difference in favour of the corticosteroid group. 
Conclusion 
Pre-operative use of corticosteroids in FESS, results in significantly reduced blood 
loss, shorter operative time and improved surgical field quality. Studies are limited on 
the intra-operative use of corticosteroids to reduce postoperative pain. Corticosteroids 
improve postoperative endoscopic scores in CRS and recurrence rates in cases of 
CRSwNP. 
 






Chronic Rhinosinusitis (CRS) is a common disabling condition resulting in significant  
healthcare cost and loss in productivity. The prevalence rate of CRS have been  
quoted from 5.5% in South America, 10.9% in Europe to about 16% in America. (1-3)  
CRS (including CRS with nasal polyps(CRSwNP)) is defined by European position 
paper on rhinosinusitis and nasal polyps (EPOS 2012), as “inflammation of the nose 
and the paranasal sinuses characterised by two or more symptoms, one of which 
should be either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip), ± facial pain/pressure, ± reduction or loss of smell; and 
either endoscopic signs of polyps and/or mucopurulent discharge primarily from 
middle meatus and/or; oedema/mucosal obstruction primarily in middle meatus, 
and/or CT changes showing mucosal changes within the osteomeatal complex and/or 
sinuses”.(4) Rhinosinusitis (RS) can be acute  when symptoms or signs subside within 
12 weeks and chronic (CRS) if these persist for more than 12 weeks.(4) CRS can be 
with or without nasal polyps (CRSwNP, CRSsNP) and affects 2-16 %(5,6) and 2-
3%(4,7) of the population respectively. 
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CRS is considered as a multifactorial disease. Environmental factors include 
pollution, smoking, fungus, bacterial and viral infections. Host factors can be, general 
factors like immune deficiencies and genetic factors; and local host factors causing 
persistent focal inflammation within the ostiomeatal complex.(8) Initial therapy for 
CRS includes nasal saline irrigation, topical and systemic corticosteroids and in cases 
of CRSsNP potentially long term antibiotics; followed by surgical intervention in 
unresponsive patients. (4,6) Corticosteroids reduce nasal mucosal inflammation and 
therefore increase drainage of infected mucosal secretions and aid the healing process. 
 
Patients who fail to respond to medical therapy are considered for Functional  
Endoscopic Sinus Surgery (FESS), which is one of the most common surgical  
procedure performed.(5,9)  Endoscopic sinus surgery was described by Stammberger(10) 
in 1985 and Kennedy(11) coined the term FESS to highlight its surgical philosophy of 
mucosal sparing . About 80% of patients have successful outcome but 20% patients 
suffer from relapse of sinusitis or complications warranting further surgical 
intervention.(12)   
 
Corticosteroids have been used preoperatively, intraoperatively and postoperatively in 
FESS for rhinosinusitis. FESS creates a conduit for topical steroids to reach the 
deeper part of the sinus cavity and act on the mucosa which was previously 
inaccessible. Intranasal corticosteroids are therefore often included in postoperative 
treatment regimens. Both local and systemic corticosteroids have also been used 
preoperatively to reduce inflammation and intraoperative bleeding, thereby improving 
surgical field.(13,14) It has also been shown that asthmatic patients who are given 
corticosteroids preoperatively have low incidence of pulmonary complications in the 
perioperative time period.(15)  Corticosteroids have also been postulated in pain 
control when used intraoperatively.(16) There are several randomised controlled trials 
evaluating the  role of corticosteroids in FESS, however, these studies have reported 
conflicting results. 
 
The aim of our study was to systematically review the existing evidence on the role of 
corticosteroids in patients with CRS undergoing FESS. The aim of our systematic 
review and meta-analysis was to determine whether preoperative corticosteroids 
affect operative parameters; intra-operative corticosteroids reduce surgical pain; and 
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postoperative corticosteroids affect patient’s symptom scores, endoscopic appearance 
and recurrence rates. 
 
Materials and Methods 
Data sources and literature search  
We conducted systematic searches for randomised controlled trials (RCTs). There 
were no language, publication year or publication status restrictions. The date of the 
last search was 20.09.2014. We searched MEDLINE, EMBASE, Web of science, 
metaRegister, Cochrane Library and ISI conference proceedings. A combination of 
MeSH and text words were used to generate two subsets of citations, one including 
studies of endoscopic surgery (‘endoscopic sinus surgery’, ‘endoscopic polypectomy’, 
‘FESS’, ‘functional endoscopic sinus surgery’) and the second including 
corticosteroids (‘corticosteroids’, ‘steroids’, ‘corticoids’, ‘dexamethasone’, 
‘fluticasone’, ‘budesonide’, ‘mometasone’, “prednisone”, “prednisolone”, 
“triamcinolone”). These subsets were combined using ‘AND’ to generate a subset of 
citations relevant to our research question. The reference lists of all known primary 
and review articles were hand searched to identify cited articles not captured by 
electronic searches. The searches were conducted independently by VP and JP. 
 
Study selection 
Two review authors (VP and JP) performed data selection and extraction based on 
predetermined criteria. Studies were selected in a two-stage process. Firstly, the titles 
and abstracts from the electronic searches were scrutinized and full manuscripts of all 
citations that were likely to meet the predefined selection criteria were obtained. Final 
inclusion or exclusion decisions were made on examination of the full manuscripts. In 
cases of duplicate publication, the most recent or complete versions were selected. We 
documented our justification for the exclusion of studies. 
 
Data extraction 
Two reviewers (JP and VP) completed data extraction. Study characteristics and 
participant features were extracted from each study regarding: characteristics of trials 
- setting, design, method of data analysis; participants - study population, number of 
participants; type of intervention: dose, route of administration, duration of treatment, 
follow-up and outcomes. Inconsistencies between reviewer’s data were resolved 
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through discussion with a third reviewer (SB) until a consensus was reached. After 
identifying the studies where additional data were needed, a request was sent by 
means of electronic mail to the corresponding author of each study. If no response 
was received, a second request was sent 2 weeks later by means of electronic mail.  
 
Data Synthesis 
Inclusion and exclusion criteria 
Studies were selected if the target population underwent FESS, and were exposed to 
corticosteroids and compared with either placebo or no corticosteroids. Only RCTs 
were included. Trials which included participants of any age, who had any               
co-morbidity including asthma and aspirin sensitivity, allergic or non-allergic, 
followed for any duration and CRS with and without polyps were included. Studies 
were excluded if the patients had taken corticosteroids in the absence of FESS.  
 
Outcomes assessed 
The outcomes were assessed under four categories. Operative outcomes, anaesthetic 
related outcomes, post-operative outcomes and risk of recurrence. Operative 
outcomes included estimated blood loss (EBL), surgical field quality and operative 
time. Postoperative outcomes included symptoms score (subjective improvement), 
endoscopic score (objective improvement) and risk of sinusitis.  
 
Assessment of risk of bias in included studies 
We assessed the methodological quality of the included studies and carried out the 
assessment of risk of bias taking into consideration: method of randomisation; 
allocation concealment; blinding; incomplete outcome data; selective outcome 
reporting; and other sources of bias.(17) We used the Cochrane ‘Risk of bias’ tool in 
RevMan 5.1,which involved describing each of these domains as reported in the trial 
and then assigning a judgement about the adequacy of each entry as low, high or 




Meta-analysis was performed in line with recommendations from the Cochrane 
Collaboration and the Quality of Reporting of Meta-analyses (QUORUM) 
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guidelines.(19,20) From each study, dichotomous outcome data were summarised in 2 x 
2 tables by two reviewers (VP, JP). The results were pooled and expressed as risk 
ratios (RR). Continuous variables were analyzed using mean differences (MD), with 
95% confidence intervals (CIs). (21)  The results were pooled using either a fixed 
effect(22) or random effect model as appropriate.(21) For symptoms scores, the 
measurements used were Sino-nasal Outcome Test Score (SNOT 21)by Rotenberg et 
al. (0-120)(23) and Jorrisen et al(12). used their own score (0-50). Results for endoscopic 
scores were derived from four studies; Cote et al(24). and Rotenberg et al.(23) used 
Lund-Kennedy endoscopic score  (LKES score;range 0-12 in one nasal cavity) (25); 
Chang et al.(26) used Philpott-Javer score (range 0-40)(27) and Jorissen et al.(12) used 
their own scoring system combining inflammation, oedema and polyps (range 0-6). 
We used standardised mean difference as a summary statistic in this meta-analysis 
because the included studies assessed the same outcome but measured it in a variety 
of ways, to standardise the results of the studies to a uniform scale before they could 
be combined.  
 Heterogeneity of the exposure effects was evaluated statistically using the I2 statistic 
to quantify heterogeneity across studies.(28) A I2 value of >50% was taken as evidence 
of substantial heterogeneity and in such cases a random effect model was used. A chi-
squared test for heterogeneity was also performed and the p- values are presented. 
 
When only medians were available, these were used as estimates of means. (29,30) 
When a study failed to present a standard deviation (SD), this statistic was either 
calculated from the standard error of the mean, 95% CI, t value or interquartile range. 
(29) Some studies provide only ranges, in such instances the SD was estimated using 
the formula total range/4. (30) Statistical analyses were performed using RevMan 5 




Of the 307 citations identified by the search, 39 were selected after initial screening.  
Following examination of the full manuscripts of these 39 studies, 21 more were 
excluded; 2 studies compared different corticosteroids, (31, 32) 4 studies were cohort 
studies with no comparison group, (33, 34, 35, 36) 4 were non-randomised comparative 
studies, (37,38,39,40) 1 study compared two different doses of a steroid, (41) 5 studies did 
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not use FESS as surgical technique, (42,43,44,45,46) 3 studies reported incomparable 
outcomes (47,48,49)and 2 were review articles (50,51). (Figure 1-Consort diagram).  
 
Eighteen studies satisfied the selection criteria and were included in this  
review.(12-14,23,24,26,52-63)   In total 1309 patients were included in this review. Four 
studies had an intrapatient control design in which one side of the nasal cavity was 
compared with the other side (n=182). (24,59,60,62) .These studies were included in the 
meta-analysis and the two groups treated as independent, and then sensitivity analysis 
was performed excluding these studies to determine the robustness of the results. The 
remaining 1127 patients were randomised to the steroid group of 607 patients and 520 
controls. Sample size per study varied across the trials and ranged from 19 to 162 
participants. Use of corticosteroids with FESS was reported for four categories; 
operative outcomes, anaesthesia related, post-operative outcomes and risk of 
recurrence. Operative outcomes were reported by three studies; (13,14,55) anaesthetic 
outcomes were reported by one study; (58) post-operative outcomes were reported by  
ten studies; (12,23,24,26,54,55,57, 59,61,62).and risk of recurrence was reported by six      
studies. (52,53,56,59,60,63) One RCT reported both on operative and post-operative 
outcomes, therefore it was included in both categories. (55) Albu et al., reported on 
patients with and without polyps; (14) data from this study is included in the meta-
analysis as Albu et al.(1) and Albu et al.(2). Albu et al(1) represent data of patients 
with CRSwNP and Albu et al (2) represent data of patients with CRSsNP. In our 
attempt to get more information about studies with inadequate data, we received no 
response from the relevant authors. (13,24,53,55) 
 
Study characteristics   
A description of the included studies is summarised in Table 1. Risk of bias from the 
included studies is represented in Figures 2 and 3. Our judgements about each risk of 
bias item, presented as percentages across all included studies, are shown in Figure 2, 
and for each risk of bias item for each included study in Figure 3. Generally, included 
studies had low risk of bias for method of randomisation and blinding, medium risk of 
bias for incomplete outcome data and selective reporting and unclear risk of bias for 





1. Operative outcomes in response to preoperative corticosteroids  
1.1 Operating time 
Data addressing this comparison were available from three studies, Sieskiewicz et     
al (13) Albu et al (14) and Wright et al. (55)Data from Wright et al(55) could not be 
included because the SD could not be calculated. Pooling the results of the remaining 
two studies (13,14) showed that, mean operative time was significantly lower in the 
steroid group compared to the non steroid group (MD -10.70 minutes; 95% CI -15.86, 
-5.55; P <0.0001; Figure 4.1). I2 was 19%, suggesting insufficient evidence of any 
significant heterogeneity (χ2=2.47,P = 0.29). 
A subgroup analysis was done according to population group which showed that in   
CRSwNP patients there was significant difference favouring steroid group (MD -
13.93 minutes;95% CI -21.02, -6.85; P =0.0001; Figure 4.1.1). I2 was 0%, suggesting 
insufficient evidence of any significant heterogeneity (χ2=0.78,P = 0.38). CRSsNP did 
not show statistically significant difference between the two groups(MD -7.07 
minutes;95% CI -14.58, -0.44; P =0.07; Figure 4.1.1). 
As Albu et al (14) used local steroids and Sieskiewicz et al (13)used systemic steroids 
we undertook a subgroup analysis looking at different modes of delivery. This 
showed a significant difference in favour of corticosteroids both local (MD -10.58 
minutes;95% CI -16.69, -4.48; P =0.0007; Figure 4.1.2) and systemic(MD -11.00 
minutes;95% CI -20.63, -1.37; P =0.03; Figure 4.1.2). In local corticosteroid subgroup 
analysis, I2 was 59%, suggesting significant heterogeneity (χ2=2.47,P = 0.12). 
 
1.2 Estimated blood loss (EBL) 
Data addressing this comparison were available from three studies,  
Sieskiewicz et al (13) Albu et al (14) and Wright et al. (55) Data from Wright et al (55) 
could not be included because the SD could not be calculated. Pooling of results from 
the remaining two studies (13,14) showed that, mean EBL was significantly lower in the 
steroid group compared to the non steroid group (MD -28.32 mls; 95% CI -40.93, -
15.72; P <0.0001; Figure 4.2). I2 was 0%, suggesting no significant heterogeneity 
(χ2=0.55, P = 0.76).  
A subgroup analysis was done according to population group which showed 
significant difference favouring the steroid group in both CRSwNP patients         
(MD-32.44 mls;95% CI -50.75, -14.12; P =0.0005; Figure 4.2.1) and CRSsNP 
 9 
patients (MD -24.63 mls;95% CI -41.99, -7.27; P =0.005; Figure 4.2.1).In CRSwNP 
subgroup analysis, I2 was 0%, suggesting no significant heterogeneity (χ2=0.18, P = 
0.67).  
As Albu et al(14) used local steroids and Sieskiewicz et al (13) used systemic steroids 
we undertook a subgroup analysis looking at different modes of delivery. This 
showed a significant difference in favour of corticosteroids both local (MD -28.41 
mls;95% CI -42.60, -14.23; P <0.0001; Figure 4.2.2) and systemic (MD -28.00 
minutes;95% CI -55.44, -0.56; P =0.05; Figure 4.2.2). In local corticosteroid subgroup 






1.3 Surgical field quality 
Data addressing this comparison were available from two studies, Sieskiewicz et  
al (13) and Albu et al. (14)Pooling of the results of these showed that, surgical field 
quality was significantly better in the steroid group as compared to no steroid group 
(MD -0.81; 95% CI -1.32, -0.30; P = 0.002; Figure 4.3). I2 was 0%, suggesting no 
significant heterogeneity (χ2=0.16, P = 0.92).  
A subgroup analysis was done according to population group which showed 
significant difference favouring steroid group in CRSwNP patients (MD -0.88; 95% 
CI -1.50, -0.26; P =0.005; Figure 4.3.1.) but not in CRSsNP patients (MD -0.66;95% 
CI -1.58, 0.26; P =0.16; Figure 4.3.1). In CRSwNP subgroup analysis, I2 was 0%, 
suggesting no significant heterogeneity (χ2=0.01, P = 0.92). 
As Albu et al(14) used local steroids and Sieskiewicz et al (13) used systemic steroids 
we undertook a subgroup analysis looking at different mode of delivery. This showed 
a significant difference in favour of corticosteroids both local (MD -0.73;95% CI        
-1.44, -0.02; P =0.04; Figure 4.3.2) and systemic(MD -0.90;95% CI -1.64, -0.16;       
P =0.02; Figure 4.3.2). In local corticosteroid subgroup analysis, I2 was 0%, 






2. Anaesthetic outcomes in response to intraoperative corticosteroids  
This was reported by one study. (58) Analysis of data showed that there was no 
significant difference in post operative pain score at 6 hours postoperatively (p=0.45) 
and 24 hours postoperatively (p=0.17) in the steroid group as compared to the non 
steroid group. 
 
3. Postoperative outcomes in response to corticosteroids   
Postoperative outcomes in the form of symptom score and endoscopic score were 
reported by twelve studies. (12,23,24,26,53-57,59,61,62) Data from Rowe-Jones et al. could not 
be pooled in the meta-analysis as their data were not homogenous with other studies 
and SD could not be calculated. (54) Individual subjective symptom outcomes mainly, 
congestion, sense of smell and rhinorrhoea were reported in two studies Stjarne et al. 
and Enhange et al. but the data could not be pooled for meta-analysis. (56,57) 
3.1 Symptom score  
 Even though postoperative symptom outcomes were reported by seven 
studies(12,23,53,54,55,56,57) data from only two studies could be pooled for the meta-
analysis. Data from Rowe-Jones et al. could not be pooled as their data was not 
homogenous with other studies. (54) They reported that overall visual analogue score, 
endoscopic polyp score and total nasal volume was significantly better in the steroid 
group at 5 years. Data from Dijkstra et al. and Wright et al., could not be included 
because the SD could not be calculated.(53,55) Dijkstra et al reported no significant 
difference in total symptom score between the steroid group and control group. (53) 
Individual Subjective symptom outcomes mainly, congestion, sense of smell and 
rhinorrhoea, were reported by Stjarne et al., Enhange et al. and Wright et al., but 
could not be pooled for meta-analysis. (55,56,57) Wright et al. concluded that there was 
no treatment effect on subjective symptoms noted between corticosteroids compared 
with placebo. (55)  Stjarne et al. reported no significant difference in baseline to end of 
treatment scores for nasal congestion and subjective sense of smell between the 
steroid and placebo group. (56)  Similarly, Enhange et al. also reported that there were 
no statistically significant differences in the changes in all these nasal parameters 
between the steroid and the placebo group after undergoing FESS. (57)   
Pooling of data from the remaining two studies(12,23) showed that there was no 
significant difference in mean post operative symptom score between the steroid 
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group compared to the non steroid group (SMD -0.01; 95% CI -0.36, 0.33;  
P = 0.94: ). I2 was 0%, suggesting no significant heterogeneity (χ2=0.36, P = 0.55). 
 
3.2 Endoscopic score - Data addressing this comparison were available from eight  
studies. (12, 23, 24, 26, 55, 59, 61, 62) Data from Wright et al., could not be included because 
the SD could not be calculated. (55) Pooling of data from the remaining seven  
studies(12,23,24,26,59,61,62)  showed that there was  significant difference in mean post 
operative endoscopic scores between the steroid group as compared to no steroid 
group (MD -0.39; 95% CI -0.60, -0.17; P = 0.0004; Figure 5.1). I2 was 0%, suggesting 
no significant heterogeneity (χ2=4.64, P = 0.59).  
A subgroup analysis was performed to assess the results according to the population 
group. Three studies reported data from mixed population, CRSwNP and  
CRSsNP, (12, 26, 59)one study reported data from CRSsNP patients (61) whereas three 
other studies showed data from CRSwNP. (23,24,62.)No significant difference between 
steroid and no corticosteroids were found in the CRSsNP  group (SMD 0.12;95% CI- 
0.52,.76; Figure 5.1).Analysis of studies reporting on CRSwNP showed significant 
difference between steroid and no steroid groups (SMD -0.62;95% CI -0.99,-0.24; 
P=0.001; Figure 5.1). I2 was 0%, suggesting no significant heterogeneity, (χ2=0.16, P 
= 0.92).Analysis of data from the mixed population group also showed significant 
difference between the steroid and no steroid groups (SMD -0.36; 95% CI -0.64,-0.08; 
P=0.01; Figure 5.1). I2 was 0%, suggesting no significant heterogeneity, (χ2=0.58, P = 
0.75) 
 
3.3 Risk of sinusitis 
Risk of sinusitis as an adverse event associated with the use of corticosteroids was 
reported by four studies. (12, 52, 54, 60)  Pooling of the results showed no significant 
difference between use of corticosteroids and no corticosteroids (RR 0.64; 95% CI 
0.32, 1.30; P = 0.22; Figure 5.2). I2 was 0%, suggesting no significant heterogeneity 
(χ2=2.01, P = 0.57).  
 
4. Recurrence risk – Risk of recurrence was reported by six studies. (52, 53, 56, 59, 60, 63) 
Pooling of results of these studies showed no significant difference between use of 
corticosteroids and no corticosteroids (RR 0.72; 95% CI 0.48, 1.08; P = 0.11; Figure 
6). I2 was 66%, suggesting significant heterogeneity (χ2=14.85, P = 0.01). 
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A subgroup analysis was performed to assess the results according to the population 
group. Three studies reported data from mixed population, CRSwNP and CRSsNP (54, 
60,61) whereas three other studies showed data from CRSwNP.(53,57,64) No significant 
difference between steroid and no corticosteroids were found in the mixed population 
group (RR 0.77; 95% CI 0.35,1.70;P=0.52;Figure 6). I2 was 71%, suggesting 
significant heterogeneity, (χ2=6.86, P = 0.03). Analysis of studies reporting on 
CRSwNP showed significant difference between steroid and no steroid groups (RR 
0.64;95% CI 0.45,0.91;P=0.01;Figure 6). I2 was 30%, suggesting no significant 





Principal findings of the review  
This systematic review and meta-analysis of randomised controlled trials for operative 
outcomes demonstrated that operative time and estimated blood loss were 
significantly lower, and surgical field quality was significantly better in the steroid 
group compared to the non steroid group. In relation to anaesthetic outcomes in 
response to intra-operative corticosteroids there was no significant difference in post 
operative pain scores between the two groups. For post-operative outcomes in 
response to the corticosteroids there was no significant difference in symptom scores 
but endoscopic scores were better for the steroid group between the two groups. The 
use of corticosteroids was not associated with an increased risk of sinusitis. There was 
no significant difference in the recurrence risk between those given corticosteroids 
and controls in mixed population group, but subgroup analysis showed favourable 
results for steroid use in cases of CRSwNP.  
 
Strengths of the review 
CRS is an inflammatory disease and therefore, corticosteroids have long been utilized 
in its management due to their potent anti-inflammatory properties. Patients who fail 
to respond to medical therapy are considered for FESS. FESS differs from traditional, 
radical and less physiological drainage procedures as it restores mucociliary clearance 
pathways and ventilation by opening the osteomeatal complex and is customized to 
disease extent. Corticosteroids have been indicated in FESS for various reasons. Our 
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review included studies reporting use of corticosteroids on the operative outcome, 
anaesthetic related outcome, postoperative outcome and recurrence risk when used 
with FESS. 
 
An important factor affecting the success of FESS is a clean surgical field. (64) Poor 
endoscopic view secondary to bleeding is associated with increased operative time, 
complications and even cessation of surgery. (64,65) Preoperative corticosteroid 
treatment has been proposed to minimise bleeding and improve surgical field. (66,67) 
Corticosteroid reduce intra operative bleeding by not just it’s anti-inflammatory effect 
but also have a positive effect on regulation of vascular tone. Various mechanisms 
explaining this positive effect of corticosteroids on the vascular tone have been 
proposed. (68) These include potentiation of action of other α adrenergic agonists like 
norepinephrine at the receptor level. Our meta-analysis for operative outcomes 
including operative time, EBL and surgical field quality showed significant benefit 
from the use of preoperative corticosteroids; both systemic (13) and topical. (14) Even 
though these studies varied in definitions of CRS (CRSsNP and CRSwNP); timing 
and commencement of corticosteroids; type, volume and route of administration of 
corticosteroids, the benefit was seen consistently in all three studies. Though we could 
not include the data from Wright et al. in our meta-analysis, these authors also 
concluded that patients who were not given pre-operative corticosteroids showed a 
higher percentage of severely inflamed mucosa and were associated with technically 
more difficult surgery. (55)  
 
Patients after FESS may experience pain which might prevent them from returning to 
normal daily activities. (69) Corticosteroids due to their potent anti-inflammatory effect 
have been proposed in the management of acute surgical and postoperative pain 
control. (16) In this respect one study was found to assess the outcome of intra-
operative corticosteroid in reducing pain after FESS. (58) This study did not show any 
benefit of using intraoperative steroid as a tool to reduce post operative pain.  
 
Comparison with other studies 
Due to the anti-inflammatory effects and excellent safety profile, topical nasal 
corticosteroids have become a common treatment modality for CRS. (70) A previous 
systematic review on use of topical corticosteroids following FESS reporting a 
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significant improvement in symptoms, endoscopic appearance and delay in polyp 
recurrence, recommended the use of nasal corticosteroids after FESS. (70) However, 
these authors did not perform a meta-analysis and summarized their recommendations 
based on individual studies. Subgroup analysis from a Cochrane review(71) on use of 
corticosteroids in CRS based on two studies (Jorrisen et al., Lavigne et al) showed 
benefit of steroid on symptom scores who had sinus surgery. (12,36) However, the study 
by Lavigne et al. had to be excluded from our study as it recruited patients with failed 
FESS, and therefore does not fulfil the inclusion criteria.  
 
Recent EPOS 2012 systematic review on the role of corticosteroids in postoperative 
treatment for adults with CRS recommended, topical corticosteroids for patients with 
CRSsNP; and both topical and oral corticosteroids in patients with CRSwNP. (4) This 
document, in a subgroup analysis showed that only patients with prior surgery for 
CRSsNP had symptom improvement but there was no improvement for those patients 
without surgery (Page 144 of the document). Similarly, in CRSwNP, patients with 
sinus surgery responded to topical steroid greater than patients without sinus surgery 
in polyp size reduction but improvement in symptoms and nasal airflow was not 
statistically different between the two subgroups (Page 170 of the document). The 
meta-analysis in the EPOS 2012 document incorporates studies which include patients 
who have had a history of sinus surgery including polypectomy. Whereas in our meta-
analysis all patients underwent FESS. Our meta-analysis showed no significant 
benefit with the use of corticosteroids in post-operative symptom outcomes.  
It has been postulated that, use of corticosteroids in the immediate post operative 
period may increase the risk of sinusitis. (32) Our meta analysis from four studies 
which used local corticosteroids, showed that there was no evidence of increased risk 
of sinusitis with steroid use in postoperative period.  We acknowledge that rare 
adverse events are possibly not detected in RCTs. However, they were extremely low 
and there was no difference in adverse events between the study groups and control 
groups in any trial. 
 
Limitations of the review 
Limitations of our systematic review include potential biases in the review process 
regarding the eligibility criteria and data analyses. The inclusion of trials studying 
mixed populations of polyps and non-polyps patients possibly brings heterogeneity. 
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We decided to include trials with mixed populations in patients with CRS with or 
without polyps, since this is inline with the definition of CRS by the European 
Position Paper 2012. (4)We also included four trial which used a paired intrapatient 
design, but treating the two groups as independent. Sensitivity analysis omitting these 
trials showed that the pooled results remained consistent. Trials required data 
imputation where standard deviations were missing and we conducted data 
imputation, as guided by the Cochrane Handbook for Systematic Reviews of 
Intervention. (28) The majority of these studies were limited to small sample size and 
adopted different symptom and endoscopic scores. Clinical diversity, including 
variability in the agents used; dose, route, duration and the delivery methods, led to 
heterogeneity in the studies included in this review.  We tried to overcome this risk of 
heterogeneity by doing a subgroup analysis where data was available but this was not 
possible to do in all comparisons. Our review even though it had significant 
heterogeneity in some outcomes, has attempted to bring the existing evidence together 
and represents the best evidence on this subject available. 
 
Clinical implications of the review 
Our systematic review and meta-analysis supports the use of pre-operative 
corticosteroids prior to FESS as it significantly reduces operative time and blood loss 
and significantly improves surgical field quality. Studies in relation to anaesthetic 
outcomes in response to intra-operative corticosteroids during FESS are limited with 
no significant benefit in post operative pain score and rescue analgesic requirement. 
More studies are required to assess the benefit of corticosteroids in this respect. 
Postoperative use of corticosteroids following FESS is not associated with any 
significant improvement in symptom scores but it is associated with better endoscopic 
scores in CRSwNP.  Use of corticosteroids was not associated with increased risk of 
sinusitis, which is reassuring.  There was no significant difference in the recurrence 
risk shown in mixed population studies of CRS, CRSwNP showed favourable results 
towards the steroid use. However, these results need to be interpreted with caution 
because these studies were limited to small sample sizes and adopted different 
symptom and endoscopic scores and reported a small number of bleeding, infection 






Preoperative use of local and systemic corticosteroids in FESS, results in significantly 
reduced blood loss, shorter operative time and improved surgical field quality. Studies 
are limited on intraoperative use of corticosteroids to reduce post operative pain. 
There is no significant benefit seen with the use of postoperative corticosteroids 
following FESS in improving symptom scores. Corticosteroids improve postoperative 
endoscopic scores. Risk of recurrence is reduced by postoperative corticosteroids in 
CRSwNP although this role is unclear in CRSsNP patients. Well-conducted large 
RCTs are required using, standardised inclusion criteria; specified dose, duration and 
route of corticosteroids; validated subjective and objective outcome measures; 
including reporting on long term recurrence rates and complications. 
 
Key Points- 
 Preoperative use of local and systemic corticosteroids in FESS, results in 
significantly reduced blood loss, shorter operative time and improved surgical 
field quality. 
 Studies are limited on intraoperative use of corticosteroids to reduce post 
operative pain.  
 The limited data available do not point to significant benefit with the use of 
postoperative corticosteroids following FESS in improving symptom scores. 
 Corticosteroids improve postoperative endoscopic scores. Risk of recurrence 
is reduced by postoperative corticosteroids in CRSwNP although this role is 
unclear in CRSsNP patients.  
 Well-conducted large RCTs are required using, standardised inclusion criteria; 
specified dose, duration and route of corticosteroids; validated subjective and 
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Table 1. Characteristics of the studies included in the review- Role of Corticosteroids 
in Functional Endoscopic Sinus Surgery - A Systematic Review and Meta-Analysis  
Figure1. Consort diagram - Study selection process for the systematic review of Role 
of Corticosteroids in Functional Endoscopic Sinus Surgery - A Systematic Review 
and Meta-Analysis  
Figure 2. ‘Risk of bias’ graph: For the systematic review – Role of Corticosteroids in 
Functional Endoscopic Sinus Surgery - A Systematic Review and Meta-Analysis - 
Each risk of bias item presented as percentages across all included studies. 
Figure 3. ‘Risk of bias’ summary: For the systematic review – Role of 
Corticosteroids in Functional Endoscopic Sinus Surgery - A Systematic Review and 
Meta-Analysis - Each risk of bias item for each included study. 
Figure 4 – Forest plot of comparison - Operative outcomes  
  
Figure 4.1.1 -Forest plot of comparison: Steroids versus No steroids.   
Outcome: 1.1 Operative time. Subgroup Analysis- Population Groups 
 
Figure 4.1.2 -Forest plot of comparison: Steroids versus No steroids.   
Outcome: 1.1 Operative time. Subgroup Analysis- Mode of Drug Delivery 
 
Figure 4.2.1 Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.2 Estimated blood loss. Subgroup Analysis- Population Group 
 
Figure 4.2.2 .Forest plot of comparison: Steroids versus No steroids 
Outcome: 1.2 Estimated blood loss .Subgroup Analysis-Mode of Drug Delivery 
 
Figure 4.3.1- Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.3 -Surgical field quality. Subgroup Analysis- Population Groups 
 
Figure 4.3.2- Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.3 -Surgical field quality. Subgroup Analysis-Mode of Drug Delivery 
 
 
Figure 5 – Forest plot of comparison – Post-operative outcomes 
 
Figure 5.1-Forest plot of comparison: Steroids versus No steroids  
Outcome: 3.2 Post operative endoscopic score 
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Figure 5.2-Forest plot of comparison: Steroids versus No steroids  
Outcome: 3.4 Risk of infection (Sinusitis) 
 




















































Age ≥18 years  
Bilateral nasal polyposis 
and/or CRS, as diagnosed 
by history, nasal endoscopy 
and CT-scan. Failure to 
conventional medical 
treatment or contra-
indications to medical 
treatment and required 
FESS for their disease. 
 
Patients who had undergone sinus surgery 
in the last 5 years and those with surgical 
contra-indications, primary ciliary 
dyskinesia, asthma requiring inhalant CS 
treatment, aspirin hypersensitivity, 
immunodeficiency or cystic fibrosis. 
Patients who received systemic and 
topical CS within 4 weeks, IM CS within 
3 months, antihistamines or leukotriene 
receptor antagonists within 10 days, nasal 
decongestants within 24 hours, and nasal 
sodium cromolyn, atropine or ipratropium 
bromide, or antifungals within 1 week 
of screening. 
Patients with contra-indications for 
intranasal or oral use of CS or 
hypersensitivity to the study drugs. 
Pregnant or breast feeding women. 
Oral 
Betamethasone 2 
mg for 7 days, 
followed by topical  
MFNS 200μg b.i.d 







spray for 7 





Total Endoscopic Scores 
Combination Endoscopic 
Scores 







Age-20-65 Yrs  
CRSwNP 
Uncompensated arterial hypertension, 
hemostatic disorders, diabetes, Deviated 








100% Total mean blood loss 
Operative field 
Surgical operative time 





CRSwNP(Grade 1 polyps) 
Coagulation disorders,  hypertension , 
cardiac disorders, unilateral sinus 
disorders, unstable asthma , regular use of  
decongestant within one month of 
surgery, simultaneous septal or inferior 
MF 200 μg (2 
sprays in each 
nostril 2 times a 
day) for 4 weeks 
preoperative. 
Placebo spray 
same dose for 
4 weeks. 
100% Operative data- 
Duration of surgery 
Surgical field 
Estimated blood loss 
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turbinate surgery, odontogenic sinusitis, 
extra mucosal mycotic sinusitis, NSAID 
intolerance, diabetes,  history of intra and 
extranasal  sinus procedure, CRS with 










Age > 18 years,  
Diagnosis of CRSwP as per 
the American Academy of 
Otolaryngology guidelines, 
A Samter’s triad phenotype, 
Failure of a minimum of 6 
months of standard medical 
management prior to ESS, 
and severe disease as 
documented by a minimum 
LKES of 8. 
Smokers, revision sinus surgery, CS for 
conditions other than CRSwP, and 
patients with diseases that were relative 
or absolute contraindications for CS use. 
 
Saline irrigation 




Rinse, using half of 
the solution twice 
daily (for a total of 







SNOT 21 Score 









Patients with CRS with 
polyposis refractory to 
medical treatment 
Ineligible for informed consent, unwilling 
or unable to comply with post operative 
visits necessary for data collection, 
intolerance to triamcinalone. 
Randomised cavity 

















Age 17 to 80 years 
Bilateral chronic 
rhinosinusitis with or 
without polyposis, failed 
maximal medical treatment, 
and required bilateral FESS 
for the treatment of CRS. 
Unilateral sinus disease, Bleeding 
disorder; Genetic disorder such as cystic 
fibrosis, Immunosuppressed, or 










Endoscopic Grading of 
postoperative Mucosal 
Healing. 








Sinonasal polyposis Not documented 
 
Steroid group-
saline lavage then  





















Age > 18 years 
Nasal polyps or CRS 
requiring treatment. 
Abnormality on CT Scan 
confirming diagnosis. 
 
Use of systemic CS or other medication 
influencing nasal mucosa during study. 
Significant anatomical abnormalities 
persisting after FESS +- Septoplasty 
History of acetylsalicylic acid intolerance, 
Pregnancy, Cystic fibrosis, serious 
concurrent disease 
Rhinosurgery in past 6 weeks. 
FPANS 800 μg BD 
(53 cases) 






Placebo BD 1 year Symptom reduction after 
FESS 
Relapse rate 
Effect of CS in post 
operative period. 





Patient with symptoms of 
CRS received 3 weeks of 
Fluticasone propionate, 100 
μg (2 spray). If failed, they 
were considered for FESS. 
Patients with 4 episodes per 
year of acute, recurrent RS 
of at least 10 days duration 
and a persistent CT scan 
score of at least 3, excluding 
an isolated polypoidal 
opacity within a sinus.CT 
scan changes had to be 
present at least 4 weeks 
after an acute infection. 
Pregnant women; age > 60 years or <16 
years; patients taking regular oral 
steroids; patients taking > 1500 μg of 
inhaled CS per day; patients with antro-
choanal or isolated polyps; patients 
requiring combined external approach 
and ESS patients requiring frontal sinus 
ostioplasty procedures; patients who had 
undergone sinus surgery within the last 
12 months; patients with mucocoeles; 
patients with tumours. 















5 years Visual analogue score 
Total sum of all 6 visual 
analogue scores, 
Endoscopic polyp, 




threshold values  
Nasal volumes. 
Rescue medication  
Failures rate 




Age-18 yrs old, 
CRSwNP, Failed or refused 
full medical treatment. 
Immunocompromissed status and 
mucociliary disorders, allergic fungal 
sinusitis. 
30 mg prednisalone 
5 days 
preoperatively and 




Placebo tablets 6mths Duration of surgery 
Difficulty of surgery 
Estimated blood loss 
Endoscopic score 
(LKES & POES) 
Symptom severity 
Questionaire score 




Age-18 years or older 
Bilateral nasal polyps. 
Polypectomy within the previous 6 
months; unhealed nasal surgery or 
trauma; > 5 previous polypectomies; or 
ongoing concurrent nasal infection, 
Mometason 








Rate of relapse 
Time to relapse 
Side Effects 
 29 
rhinitis medicamentosa, hereditary 
mucociliary dysfunction, nasal structural 
abnormalities, or an idiosyncratic reaction 
to CS. Active or latent pulmonary 
tuberculosis; other significant medical 
conditions that could interfere with 
evaluations (eg, cystic fibrosis); or a 
history of hypersensitivity to the study 
medication, Women who are Pregnant, 















Age 18 years 
Bilateral nasal polyps and 
Asthma 
 
Unfit for GA; Polypectomy in last 6 
months; Illness or medication that may 
interfere with the study; Idiosyncratic 
reaction to CS; Prohibited medication 
within wash-out period; Participated in 
clinical trial within 30 days 
Pregnant or lactating women; Women of 
child bearing potential not using adequate 
anti-contraceptive method 
Study personnel or patients related to 
study personnel; Aspirin Senstivity 
Fluticasone 
proprionate nasal 
drops  400 μg  b.i.d 





Nasal symptoms scores. 
Asthma symptoms score. 
Peak expiratory flow rate 
Need of b2-agonists. 
Peak nasal inspiratory 
flow (PNIF) 
Butanol threshold test for 
olfactory function. 
Nasal endoscopy. 








All patients undergoing 
elective FESS with ASA1/2. 
 
 
Patients under 16 yrs, 
Previous systemic CS treatment for > 3 
months at any time or within 1 month 
before randomization. 
Grade 3 nasal polyps. 











Postoperative pain score- 
PACU – 6 and 24- Hours. 
Patients needing rescue 
anaesthesia. 




Adult patients with or 
without nasal polyps 
scheduled to undergo 
primary or revision FESS, 
and in whom placement of 
the sinus stents was deemed 
to be both feasible and 
Patients were excluded if they had known 
history of intolerance to corticosteroids, 
an oral steroid–dependent condition, a 
history of immune deficiency, insulin-




stents releasing a 
total dose of      
370 μg of MF is 











medically appropriate of polylactide-co-
glycolide, which 
releases the MF by 









CRS with or without nasal 
polyps 
Patients were excluded for a known 
history of immune deficiency, insulin-
dependent diabetes, allergy or intolerance 
to corticosteroids, oral steroid-dependent 
condition, clinical evidence of acute 
bacterial sinusitis, or clinical evidence of 
invasive fungal sinusitis. Ocular 
exclusionary criteria included 
history or diagnosis of glaucoma or 
ocular hypertension,closed angle, 
presence of cataracts grade +3 or higher, 




contains 370 μg 
mometasone 
furoate, embedded 



















Age ≥18 years old 
 Chronic rhinosinusitis 
persistent symptoms despite 
medical management 
undergoing  minimum 
bilateral ESS . 
Nasal polyposis , uncorrectable 
coagulopathy; emergency surgical 





mixture .4 mL of 
dexamethasone (4 
mg/mL) in 4 mL 
of sterile water. 
Sinu-Foam 
syringes with  
placebo 










CRSwNP failing medical 
treatment and undergoing 
FESS 
Revision Endoscopic Sinus Surgery 
Cases. 
Immunosuppressed Patients 














Passali et al(63) 
2003 
Intervention -33 
Patient with Grade 3 
CRSwNP refractory to 
medical treatment 







3-6yrs Recurrence rates 
Rhinomanometry results 
 31 
Controls-40 30 days 
Mometasone Furoate (MF), Post Anaesthetic Care Unit (PACU), Lund-Kennedy endoscopic score (LKES), Perioperative Sinus Endoscopy Scores POSE, Fluticasone 
Propionate Aqueous Nasal Spray (FPANS) , Sino-Nasal Outcome Test Score (SNOT  21),Lund Mackay CT Scan Score (LM Score), Adernocorticotropic Harmone (ACTH)  




Figure 4 – Forest plot of comparison - Operative outcomes  
 
Figure 4.1.1 Forest plot of comparison: Steroids versus No steroids   
Outcome: 1.1 Operative time. Subgroup Analysis- Population Groups 
 
Figure 4.1.2 Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.1 Operative time. Subgroup Analysis-Mode of Drug Delivery 
 
Figure 4.2.1 Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.2 Estimated blood loss. Subgroup Analysis- Population Group 
Figure 4.2.2 .Forest plot of comparison: Steroids versus No steroids 
Outcome: 1.2 Estimated blood loss .Subgroup Analysis-Mode of Drug Delivery 
 
Figure 4.3.1- Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.3 -Surgical field quality. Subgroup Analysis- Population Groups 
 
Figure 4.3.2- Forest plot of comparison: Steroids versus No steroids  
Outcome: 1.3 -Surgical field quality. Subgroup Analysis-Mode of Drug Delivery 
Figure 5 – Forest plot of comparison – Post-operative outcomes 
 
Figure 5.1 Forest plot of comparison: Steroids versus No steroids  
Outcome: 3.2 Post operative endoscopic score 
 
Figure 5.2 Forest plot of comparison: Steroids versus No steroids  
Outcome: 3.4 Risk of infection (Sinusitis) 
 
Figure 6 – Forest plot of comparison – Recurrence risk 
 
Figure 2-Risk of bias graph: review authors' judgments about each risk of bias 
item presented as percentages across all included studies 
 
Figure 3-Risk of bias summary: review authors' judgments about each risk of bias 
item for each included study 
 
Total number of citations retrieved from electronic 
searches and from examination of reference lists of 
primary and review articles: (n=307) 
Citations excluded after screening 
titles and/ or abstracts: (n=268) 
Studies excluded with reasons (n=21) 
- Compared two different steroids (n=2)(31,32) 
-Cohort studies with no comparison group    
(n=3) (33,34,35,36) 
- Non randomised studies (n=4) (37,38,39,40) 
-Compared two different doses of a steroid (n=1) (41) 
-Surgical techniques not clear(n=5) (42,43,44,45,46)  
-Studies reporting incomparable outcomes        
(n=3) (47,48,49) 






Full manuscripts retrieved for 
detailed evaluation: (n=39) 
Randomised control trials with suitable information, by outcome (n=18) 
1. RCTs for operative outcomes (n=3) (13,14,55)   
2. RCTs for anaesthetic outcomes (n=1) (58)   
3. RCTs for post-operative outcome and Recurrence Rate (n =14)(12,23,24,26,52-57,59-63)  
* Wright et al (55) reported on operative and post-operative outcomes hence mentioned 
twice. 
Figure1. Consort diagram - Study selection process for the systematic review of Role of 
Corticosteroids in Functional Endoscopic Sinus Surgery- A Systematic Review and Meta-
Analysis  
